Search

Your search keyword '"Lalive, Patrice"' showing total 389 results
Start Over Author "Lalive, Patrice" Publication Year Range Last 10 years
389 results on '"Lalive, Patrice"'

4. Impact of inflammatory response in the acute phase of COVID-19 on predicting objective and subjective post-COVID fatigue

Author

Péron, Julie, primary, Nuber-Champier, Anthony, additional, Breville, Gautier, additional, Voruz, Philippe, additional, de Alcântara, Isabele Jacot, additional, Lalive, Patrice, additional, Allali, Gilles, additional, Benzakour, Lamyae, additional, Braillard, Olivia, additional, Nehme, Mayssam, additional, Coen, Matteo, additional, Serratrice, Jacques, additional, Reny, Jean-Luc, additional, Pugin, Jérôme, additional, Guessous, Idris, additional, Landis, Basile, additional, Assal, Frédéric, additional, and Peron, Julie, additional

Published
2024
Full Text
View/download PDF

7. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study

Author

Aeschbacher, Stefanie, Barakovic, Muhamed, Buser, Andreas, Chan, Andrew, Disanto, Giulio, D'Souza, Marcus, Du Pasquier, Renaud, Findling, Oliver, Galbusera, Riccardo, Hrusovsky, Kevin, Khalil, Michael, Lorscheider, Johannes, Mathias, Amandine, Orleth, Annette, Radue, Ernst-Wilhelm, Rahmanzadeh, Reza, Sinnecker, Tim, Subramaniam, Suvitha, Vehoff, Jochen, Wellmann, Sven, Wuerfel, Jens, Zecca, Chiara, Benkert, Pascal, Meier, Stephanie, Schaedelin, Sabine, Manouchehrinia, Ali, Yaldizli, Özgür, Maceski, Aleksandra, Oechtering, Johanna, Achtnichts, Lutz, Conen, David, Derfuss, Tobias, Lalive, Patrice H, Mueller, Christian, Müller, Stefanie, Naegelin, Yvonne, Oksenberg, Jorge R, Pot, Caroline, Salmen, Anke, Willemse, Eline, Kockum, Ingrid, Blennow, Kaj, Zetterberg, Henrik, Gobbi, Claudio, Kappos, Ludwig, Wiendl, Heinz, Berger, Klaus, Sormani, Maria Pia, Granziera, Cristina, Piehl, Fredrik, Leppert, David, and Kuhle, Jens

Published
2022
Full Text
View/download PDF

8. MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial

Author

Janiaud, Perrine, Zecca, Chiara, Salmen, Anke, Benkert, Pascal, Schädelin, Sabine, Orleth, Annette, Demuth, Lilian, Maceski, Aleksandra Maleska, Granziera, Cristina, Oechtering, Johanna, Leppert, David, Derfuss, Tobias, Achtnichts, Lutz, Findling, Oliver, Roth, Patrick, Lalive, Patrice, Uginet, Marjolaine, Müller, Stefanie, Pot, Caroline, and Hoepner, Robert

Subjects
MAGNETIC resonance imaging, QUALITY of life, PATIENT preferences, MULTIPLE sclerosis, DRUG therapy
Abstract

Background: Treatment decisions for persons with relapsing–remitting multiple sclerosis (RRMS) rely on clinical and radiological disease activity, the benefit-harm profile of drug therapy, and preferences of patients and physicians. However, there is limited evidence to support evidence-based personalized decision-making on how to adapt disease-modifying therapy treatments targeting no evidence of disease activity, while achieving better patient-relevant outcomes, fewer adverse events, and improved care. Serum neurofilament light chain (sNfL) is a sensitive measure of disease activity that captures and prognosticates disease worsening in RRMS. sNfL might therefore be instrumental for a patient-tailored treatment adaptation. We aim to assess whether 6-monthly sNfL monitoring in addition to usual care improves patient-relevant outcomes compared to usual care alone. Methods: Pragmatic multicenter, 1:1 randomized, platform trial embedded in the Swiss Multiple Sclerosis Cohort (SMSC). All patients with RRMS in the SMSC for ≥ 1 year are eligible. We plan to include 915 patients with RRMS, randomly allocated to two groups with different care strategies, one of them new (group A) and one of them usual care (group B). In group A, 6-monthly monitoring of sNfL will together with information on relapses, disability, and magnetic resonance imaging (MRI) inform personalized treatment decisions (e.g., escalation or de-escalation) supported by pre-specified algorithms. In group B, patients will receive usual care with their usual 6- or 12-monthly visits. Two primary outcomes will be used: (1) evidence of disease activity (EDA3: occurrence of relapses, disability worsening, or MRI activity) and (2) quality of life (MQoL-54) using 24-month follow-up. The new treatment strategy with sNfL will be considered superior to usual care if either more patients have no EDA3, or their health-related quality of life increases. Data collection will be embedded within the SMSC using established trial-level quality procedures. Discussion: MultiSCRIPT aims to be a platform where research and care are optimally combined to generate evidence to inform personalized decision-making in usual care. This approach aims to foster better personalized treatment and care strategies, at low cost and with rapid translation to clinical practice. Trial registration: ClinicalTrials.gov NCT06095271. Registered on October 23, 2023 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study

Author

Dekeyser, Cathérine, primary, Hautekeete, Matthias, additional, Cambron, Melissa, additional, Van Pesch, Vincent, additional, Patti, Francesco, additional, Kuhle, Jens, additional, Khoury, Samia, additional, Lechner Scott, Jeanette, additional, Gerlach, Oliver, additional, Lugaresi, Alessandra, additional, Maimone, Davide, additional, Surcinelli, Andrea, additional, Grammond, Pierre, additional, Kalincik, Tomas, additional, Habek, Mario, additional, Willekens, Barbara, additional, Macdonell, Richard, additional, Lalive, Patrice, additional, Csepany, Tunde, additional, Butzkueven, Helmut, additional, Boz, Cavit, additional, Tomassini, Valentina, additional, Foschi, Matteo, additional, Sánchez-Menoyo, José Luis, additional, Altintas, Ayse, additional, Mrabet, Saloua, additional, Iuliano, Gerardo, additional, Sa, Maria Jose, additional, Alroughani, Raed, additional, Karabudak, Rana, additional, Aguera-Morales, Eduardo, additional, Gray, Orla, additional, de Gans, Koen, additional, van der Walt, Anneke, additional, McCombe, Pamela A, additional, Deri, Norma, additional, Garber, Justin, additional, Al-Asmi, Abdullah, additional, Skibina, Olga, additional, Duquette, Pierre, additional, Cartechini, Elisabetta, additional, Spitaleri, Daniele, additional, Gouider, Riadh, additional, Soysal, Aysun, additional, Van Hijfte, Liesbeth, additional, Slee, Mark, additional, Amato, Maria Pia, additional, Buzzard, Katherine, additional, and Laureys, Guy, additional

Published
2024
Full Text
View/download PDF

11. Persistence and emergence of new neuropsychological deficits following SARS-CoV-2 infection: A follow-up assessment of the Geneva COVID-COG cohort

Author

Voruz, Philippe, primary, de Alcântara, Isabele Jacot, additional, Nuber-Champier, Anthony, additional, Cionca, Alexandre, additional, Guérin, Delphine, additional, Allali, Gilles, additional, Benzakour, Lamyae, additional, Lalive, Patrice H, additional, Lövblad, Karl-Olof, additional, Braillard, Olivia, additional, Nencha, Umberto, additional, Nehme, Mayssam, additional, Coen, Matteo, additional, Serratrice, Jacques, additional, Reny, Jean-Luc, additional, Pugin, Jérôme, additional, Guessous, Idris, additional, Landis, Basile N, additional, Assal, Frédéric, additional, and Péron, Julie A, additional

Published
2024
Full Text
View/download PDF

13. Besonderheiten der Immuntherapie der Multiplen Sklerose in der Schweiz: Update

Author

Friedli, Christoph, primary, Salmen, Anke, additional, Robert Hoepner, PD, additional, Achtnichts, Lutz, additional, Sandra Bigi, PD, additional, Derfuss, Tobias, additional, Gobbi, Claudio, additional, Kamber, Nicole, additional, Kamm, Christian, additional, Kuhle, Jens, additional, Lalive, Patrice, additional, Müller, Stefanie, additional, Athina Papadopoulou, PD, additional, Pot, Caroline, additional, Zecca, Chiara, additional, Chan, Andrew, additional, and Zusammenarbeit mit, in, additional

Published
2024
Full Text
View/download PDF

14. Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS

Author

Cagol, Alessandro, primary, Benkert, Pascal, additional, Melie-Garcia, Lester, additional, Schaedelin, Sabine A., additional, Leber, Selina, additional, Tsagkas, Charidimos, additional, Barakovic, Muhamed, additional, Galbusera, Riccardo, additional, Lu, Po-Jui, additional, Weigel, Matthias, additional, Ruberte, Esther, additional, Radue, Ernst-Wilhelm, additional, Yaldizli, Özgür, additional, Oechtering, Johanna, additional, Lorscheider, Johannes, additional, D'Souza, Marcus, additional, Fischer-Barnicol, Bettina, additional, Müller, Stefanie, additional, Achtnichts, Lutz, additional, Vehoff, Jochen, additional, Disanto, Giulio, additional, Findling, Oliver, additional, Chan, Andrew, additional, Salmen, Anke, additional, Pot, Caroline, additional, Bridel, Claire, additional, Zecca, Chiara, additional, Derfuss, Tobias, additional, Lieb, Johanna M., additional, Remonda, Luca, additional, Wagner, Franca, additional, Vargas, Maria Isabel, additional, Du Pasquier, Renaud A., additional, Lalive, Patrice H., additional, Pravatà, Emanuele, additional, Weber, Johannes, additional, Cattin, Philippe C., additional, Absinta, Martina, additional, Gobbi, Claudio, additional, Leppert, David, additional, Kappos, Ludwig, additional, Kuhle, Jens, additional, and Granziera, Cristina, additional

Published
2024
Full Text
View/download PDF

16. Multicentric evaluation of a specific intrathecal anti-Treponema pallidumIgG index as a diagnostic biomarker of neurosyphilis: results from a retro-prospective case–control study

Author

Alberto, Chloé, primary, Lambeng, Nathalie, additional, Deffert, Christine, additional, Breville, Gautier, additional, Gayet-Ageron, Angèle, additional, Lalive, Patrice, additional, Calmy, Alexandra, additional, Coste, Alix, additional, Papadimitriou-Olivgeris, Matthaios, additional, Braun, Dominique, additional, Lienhard, Reto, additional, Bosshard, Philipp Peter, additional, Fontao, Lionel, additional, and Toutous Trellu, Laurence, additional

Published
2023
Full Text
View/download PDF

18. Glatiramer acetate treatment negatively regulates type I interferon signaling

Author

Molnarfi, Nicolas, Prod'homme, Thomas, Schulze-Topphoff, Ulf, Spencer, Collin M, Weber, Martin S, Patarroyo, Juan C, Lalive, Patrice H, and Zamvil, Scott S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Immunology, Neurosciences, Autoimmune Disease, Multiple Sclerosis, Neurodegenerative, Brain Disorders, Aetiology, 2.1 Biological and endogenous factors, Inflammatory and immune system
Abstract

ObjectiveGlatiramer acetate (GA; Copaxone), a disease-modifying therapy for multiple sclerosis (MS), promotes development of anti-inflammatory (M2, type II) monocytes that can direct differentiation of regulatory T cells. We investigated the innate immune signaling pathways that participate in GA-mediated M2 monocyte polarization.MethodsMonocytes were isolated from myeloid differentiation primary response gene 88 (MyD88)-deficient, Toll-IL-1 receptor domain-containing adaptor inducing interferon (IFN)-β (TRIF)-deficient, IFN-α/β receptor subunit 1 (IFNAR1)-deficient, and wild-type (WT) mice and human peripheral blood. GA-treated monocytes were stimulated with Toll-like receptor ligands, then evaluated for activation of kinases and transcription factors involved in innate immunity, and secretion of proinflammatory cytokines. GA-treated mice were evaluated for cytokine secretion and susceptibility to experimental autoimmune encephalomyelitis.ResultsGA-mediated inhibition of proinflammatory cytokine production by monocytes occurred independently of MyD88 and nuclear factor-κB, but was blocked by TRIF deficiency. Furthermore, GA did not provide clinical benefit in TRIF-deficient mice. GA inhibited activation of p38 mitogen-activated protein kinase, an upstream regulator of activating transcription factor (ATF)-2, and c-Jun N-terminal kinase 1, which regulates IFN regulatory factor 3 (IRF3). Consequently, nuclear translocation of ATF-2 and IRF3, components of the IFN-β enhanceosome, was impaired. Consistent with these observations, GA inhibited production of IFN-β in vivo in WT mice, but did not modulate proinflammatory cytokine production by monocytes from IFNAR1-deficient mice.ConclusionOur results demonstrate that GA inhibits the type I IFN pathway in M2 polarization of monocytes independently of MyD88, providing an important mechanism connecting innate and adaptive immune modulation in GA therapy and valuable insight regarding its potential use with other MS treatments.

Published
2015

21. Complement Activation Is Associated With Disease Severity in Multiple Sclerosis.

Author

Oechtering, Johanna, Stein, Kerstin, Schaedelin, Sabine A., Maceski, Aleksandra M., Orleth, Annette, Meier, Stephanie, Willemse, Eline, Qureshi, Ferhan, Heijnen, Ingmar, Regeniter, Axel, Derfuss, Tobias, Benkert, Pascal, D'Souza, Marcus, Limberg, Marguerite, Fischer-Barnicol, Bettina, Achtnichts, Lutz, Mueller, Stefanie, Salmen, Anke, Lalive, Patrice H., and Bridel, Claire

Published
2024
Full Text
View/download PDF

22. Multicentric evaluation of a specific intrathecal anti-Treponema pallidum IgG index as a diagnostic biomarker of neurosyphilis: results from a retro-prospective case-control study.

Author

Alberto, Chloé, Lambeng, Nathalie, Deffert, Christine, Breville, Gautier, Gayet-Ageron, Angèle, Lalive, Patrice, Calmy, Alexandra, Coste, Alix, Papadimitriou-Olivgeris, Matthaios, Braun, Dominique, Lienhard, Reto, Bosshard, Philipp Peter, Fontao, Lionel, and Trellu, Laurence Toutous

Published
2024
Full Text
View/download PDF

25. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Author

Sharmin, Sifat, primary, Roos, Izanne, additional, Simpson-Yap, Steve, additional, Malpas, Charles, additional, Sánchez, Marina M, additional, Ozakbas, Serkan, additional, Horakova, Dana, additional, Havrdova, Eva K, additional, Patti, Francesco, additional, Alroughani, Raed, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Boz, Cavit, additional, Zakaria, Magd, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Weinstock-Guttman, Bianca, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Terzi, Murat, additional, Amato, Maria Pia, additional, Karabudak, Rana, additional, Grand’Maison, Francois, additional, Khoury, Samia J, additional, Grammond, Pierre, additional, Lechner-Scott, Jeannette, additional, Buzzard, Katherine, additional, Skibina, Olga, additional, van der Walt, Anneke, additional, Butzkueven, Helmut, additional, Turkoglu, Recai, additional, Altintas, Ayse, additional, Maimone, Davide, additional, Kermode, Allan, additional, Shalaby, Nevin, additional, Pesch, Vincent V, additional, Butler, Ernest, additional, Sidhom, Youssef, additional, Gouider, Riadh, additional, Mrabet, Saloua, additional, Gerlach, Oliver, additional, Soysal, Aysun, additional, Barnett, Michael, additional, Kuhle, Jens, additional, Hughes, Stella, additional, Sa, Maria J, additional, Hodgkinson, Suzanne, additional, Oreja-Guevara, Celia, additional, Ampapa, Radek, additional, Petersen, Thor, additional, Ramo-Tello, Cristina, additional, Spitaleri, Daniele, additional, McCombe, Pamela, additional, Taylor, Bruce, additional, Prevost, Julie, additional, Foschi, Matteo, additional, Slee, Mark, additional, McGuigan, Chris, additional, Laureys, Guy, additional, Hijfte, Liesbeth V, additional, de Gans, Koen, additional, Solaro, Claudio, additional, Oh, Jiwon, additional, Macdonell, Richard, additional, Aguera-Morales, Eduardo, additional, Singhal, Bhim, additional, Gray, Orla, additional, Garber, Justin, additional, Wijmeersch, Bart V, additional, Simu, Mihaela, additional, Castillo-Triviño, Tamara, additional, Sanchez-Menoyo, Jose L, additional, Khurana, Dheeraj, additional, Al-Asmi, Abdullah, additional, Al-Harbi, Talal, additional, Deri, Norma, additional, Fragoso, Yara, additional, Lalive, Patrice H, additional, Sinnige, L G F, additional, Shaw, Cameron, additional, Shuey, Neil, additional, Csepany, Tunde, additional, Sempere, Angel P, additional, Moore, Fraser, additional, Decoo, Danny, additional, Willekens, Barbara, additional, Gobbi, Claudio, additional, Massey, Jennifer, additional, Hardy, Todd, additional, Parratt, John, additional, and Kalincik, Tomas, additional

Published
2023
Full Text
View/download PDF

27. Obstructive sleep apnea: a major risk factor for COVID-19 encephalopathy?

Author

Breville, Gautier, primary, Herrmann, François, additional, Adler, Dan, additional, Deffert, Christine, additional, Bommarito, Giulia, additional, Stancu, Patrick, additional, Accorroni, Alice, additional, Uginet, Marjolaine, additional, Assal, Frederic, additional, Tamisier, Renaud, additional, Lalive, Patrice H., additional, Pepin, Jean-Louis, additional, Lövblad, Karl-Olof, additional, and Allali, Gilles, additional

Published
2023
Full Text
View/download PDF

30. c-Met + Cytotoxic T Lymphocytes Exhibit Enhanced Cytotoxicity in Mice and Humans In Vitro Tumor Models.

Author

Benkhoucha, Mahdia, Tran, Ngoc Lan, Senoner, Isis, Breville, Gautier, Fritah, Hajer, Migliorini, Denis, Dutoit, Valérie, and Lalive, Patrice H.

Subjects
CYTOTOXIC T cells, IMMUNE checkpoint proteins, HUMAN cloning, CYTOTOXINS, IPILIMUMAB, HEPATOCYTE growth factor, MICROPHTHALMIA-associated transcription factor, MELANOMA
Abstract

CD8+ cytotoxic T lymphocytes (CTLs) play a crucial role in anti-tumor immunity. In a previous study, we identified a subset of murine effector CTLs expressing the hepatocyte growth factor (HGF) receptor, c-Met (c-Met+ CTLs), that are endowed with enhanced cytolytic capacity. HGF directly inhibited the cytolytic function of c-Met+ CTLs, both in 2D in vitro assays and in vivo, leading to reduced T cell responses against metastatic melanoma. To further investigate the role of c-Met+ CTLs in a three-dimensional (3D) setting, we studied their function within B16 melanoma spheroids and examined the impact of cell–cell contact on the modulation of inhibitory checkpoint molecules' expression, such as KLRG1, PD-1, and CTLA-4. Additionally, we evaluated the cytolytic capacity of human CTL clones expressing c-Met (c-Met+) and compared it to c-Met− CTL clones. Our results indicated that, similar to their murine counterparts, c-Met+ human CTL clones exhibited increased cytolytic activity compared to c-Met− CTL clones, and this enhanced function was negatively regulated by the presence of HGF. Taken together, our findings highlight the potential of targeting the HGF/c-Met pathway to modulate CTL-mediated anti-tumor immunity. This research holds promise for developing strategies to enhance the effectiveness of CTL-based immunotherapies against cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis.

Author

Abdelhak, Ahmed, Benkert, Pascal, Schaedelin, Sabine, Boscardin, W. John, Cordano, Christian, Oechtering, Johanna, Ananth, Kirtana, Granziera, Cristina, Melie-Garcia, Lester, Montes, Shivany Condor, Beaudry-Richard, Alexandra, Achtnichts, Lutz, Oertel, Frederike C., Lalive, Patrice H., Leppert, David, Müller, Stefanie, Henry, Roland G., Pot, Caroline, Matthias, Amandine, and Salmen, Anke

Published
2023
Full Text
View/download PDF

35. Serum Glial Fibrillary Acidic Protein compared with Neurofilament Light Chain as Biomarker for Multiple Sclerosis Disease Progression (P5-3.016)

Author

Meier, Stephanie, primary, Benkert, Pascal, additional, Maceski, Aleksandra Maleska, additional, Schaedelin, Sabine, additional, Oechtering, Johanna, additional, Melie-Garcia, Lester, additional, Cagol, Alessandro, additional, Barakovic, Muhamed, additional, Galbusera, Riccardo, additional, Achtnichts, Lutz, additional, Lalive, Patrice H., additional, Bridel, Claire, additional, Müller, Stefanie, additional, Pot, Caroline, additional, Salmen, Anke, additional, Disanto, Giulio, additional, Zecca, Chiara, additional, Abdelhak, Ahmed, additional, Barro, Christian, additional, Thebault, Simon, additional, D’Souza, Marcus, additional, Derfuss, Tobias, additional, Orleth, Annette, additional, Khalil, Michael, additional, Yaldizli, Özguer, additional, Hermesdorf, Marco, additional, Wiendl, Heinz, additional, Piehl, Fredrik, additional, Fischer, Urs, additional, Kappos, Ludwig, additional, Gobbi, Claudio, additional, Granziera, Cristina, additional, Leppert, David, additional, Willemse, Eline A.J., additional, and Kuhle, Jens, additional

Published
2023
Full Text
View/download PDF

37. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

Author

Meier, Stephanie, primary, Willemse, Eline A.J., additional, Schaedelin, Sabine, additional, Oechtering, Johanna, additional, Lorscheider, Johannes, additional, Melie-Garcia, Lester, additional, Cagol, Alessandro, additional, Barakovic, Muhamed, additional, Galbusera, Riccardo, additional, Subramaniam, Suvitha, additional, Barro, Christian, additional, Abdelhak, Ahmed, additional, Thebault, Simon, additional, Achtnichts, Lutz, additional, Lalive, Patrice, additional, Müller, Stefanie, additional, Pot, Caroline, additional, Salmen, Anke, additional, Disanto, Giulio, additional, Zecca, Chiara, additional, D’Souza, Marcus, additional, Orleth, Annette, additional, Khalil, Michael, additional, Buchmann, Arabella, additional, Du Pasquier, Renaud, additional, Yaldizli, Özgür, additional, Derfuss, Tobias, additional, Berger, Klaus, additional, Hermesdorf, Marco, additional, Wiendl, Heinz, additional, Piehl, Fredrik, additional, Battaglini, Marco, additional, Fischer, Urs, additional, Kappos, Ludwig, additional, Gobbi, Claudio, additional, Granziera, Cristina, additional, Bridel, Claire, additional, Leppert, David, additional, Maleska Maceski, Aleksandra, additional, Benkert, Pascal, additional, and Kuhle, Jens, additional

Published
2023
Full Text
View/download PDF

39. Multicentric evaluation of a specific intrathecal anti-Treponema pallidumIgG index as a diagnostic biomarker of neurosyphilis: results from a retro-prospective case–control study

Author

Alberto, Chloé, Lambeng, Nathalie, Deffert, Christine, Breville, Gautier, Gayet-Ageron, Angèle, Lalive, Patrice, Calmy, Alexandra, Coste, Alix, Papadimitriou-Olivgeris, Matthaios, Braun, Dominique, Lienhard, Reto, Bosshard, Philipp Peter, Fontao, Lionel, and Toutous Trellu, Laurence

Abstract

Background and objectivesThe diagnosis of neurosyphilis (NS) lacks a true ‘gold standard’, making the diagnosis challenging while consequences of a misdiagnosis are potentially severe. The aim of this study was to evaluate the diagnostic performance of measuring an antibody index (AI) for the intrathecal synthesis of specific anti-Treponema pallidum(T. pallidum) IgG for the diagnosis of NS.MethodsSpecific anti-T. pallidumIgG were measured simultaneously in paired cerebrospinal fluid (CSF)–serum samples collected retrospectively and prospectively between 2007 and 2022, from patients suspected of NS, in Switzerland. An AI was calculated to account for blood–brain barrier integrity. Area under the receiver operating characteristic curve, sensitivity/specificity and positive/negative predictive values of AI test were estimated. Two NS definitions were used: NS1 included patients with NS suspicion presenting with neurological symptoms and/or acute neurosensory signs, and positive T. PallidumHemagglutinations Assay (TPHA)/T. pallidumparticle agglutination assay (TPPA) serology and CSF-TPHA/TPPA ≥320, and either CSF-leucocytes >5 cells/mm3and/or CSF-protein >0.45 g/L and/or a reactive CSF-venereal disease research laboratory (VDRL)/rapid plasma reagin (RPR) test. NS2 included patients with suspected NS presenting with acute ocular and/or otologic symptoms, and positive TPHA/TPPA serology, and a favourable response to NS treatment. Controls were patients diagnosed with any other central nervous system (CNS) pathologies and with positive TPHA/TPPA serology.ResultsThe study included 71 NS (43 NS1 and 28 NS2) and 110 controls. With a threshold of ≥1.7, sensitivity and specificity of the specific AI test were 90.7% (CI 77.7 to 97.4) and 100% (CI 96.7 to 100.0), respectively, for NS1 and 14.3% (CI 4 to 32.7) and 100% (CI 96.7 to 100.0) for NS2. In patients suspected of NS with a CNS involvement (NS1 group), NS could be confirmed by the positivity of this specific AI.ConclusionsMeasurement of an intrathecal synthesis index of specific anti-T. pallidumIgG in patients with CSF inflammatory signs appears to be a valuable diagnostic test. However, in otic or ocular syphilis, presenting few CSF abnormalities, AI is not sufficient alone to confirm NS diagnosis.Trial registrationSwiss Association of Research Ethics Committees number 2019-00232.

Published
2024
Full Text
View/download PDF

40. Personality as a Predictor of Disability in Multiple Sclerosis.

Author

Alcântara, Isabele Jacot de, Voruz, Philippe, Allali, Gilles, Fragnoli, Chloé, Antoniou, Maria Paraskevi, Lalive, Patrice Henri, and Péron, Julie Anne

Subjects
DISABILITIES, MULTIPLE sclerosis, PERSONALITY, PATIENT compliance, PERSONALITY disorders, EXTRAVERSION
Abstract

Objective As personality changes and personality disorders are frequently observed in multiple sclerosis (MS), personality may be a prognostic factor for this disease. The present study investigated the influence of personality on disability, progression, and treatment adherence in MS. Method Personality was assessed in 41 patients with Relapsing–Remitting MS (30 females; mean age = 42.63 years) using the NEO Personality Inventory—3rd edition. Disability was measured with the Expanded Disability Status Scale, and treatment adherence information was collected from the Swiss MS Cohort. Correlation, multiple linear and partial least square regressions were performed to examine relations between personality, disability, and treatment adherence in MS. Results After accounting for age and time since disease onset, our analysis revealed that Neuroticism (β  = 0.32, p  = 0.01) and its Vulnerability facet (β  = 0.28, p  < 0.05) predicted greater disability, whereas Extraversion (β  = −0.25, p  = 0.04) and its Activity facet (β  = −0.23, p  < 0.05) predicted milder disability. Regarding disability progression, correlational analysis revealed that it was negatively correlated with Extraversion (r  = −0.44, p  = 0.02) and the Feelings facet of Openness (r  = −0.41, p  = 0.03), but regressions failed to highlight any predictive links. No significant results could be demonstrated for treatment adherence. Conclusions Overall, our study showed that some personality traits can impact disability in MS, indicating that these should be considered in clinical practice, as they could be used to adapt and improve patients' clinical support. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. Markers of limbic system damage following SARS-CoV-2 infection

Author

Thomasson, Marine, primary, Voruz, Philippe, additional, Cionca, Alexandre, additional, Jacot de Alcântara, Isabele, additional, Nuber-Champier, Anthony, additional, Allali, Gilles, additional, Benzakour, Lamyae, additional, Lalive, Patrice H, additional, Lövblad, Karl-Olof, additional, Braillard, Olivia, additional, Nehme, Mayssam, additional, Coen, Matteo, additional, Serratrice, Jacques, additional, Reny, Jean-Luc, additional, Pugin, Jérôme, additional, Guessous, Idris, additional, Landis, Basile N, additional, Griffa, Alessandra, additional, Van De Ville, Dimitri, additional, Assal, Frederic, additional, and Péron, Julie A, additional

Published
2023
Full Text
View/download PDF

43. Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022

Author

Friedli, Christoph, primary, Salmen, Anke, additional, Hoepner, Robert, additional, Achtnichts, Lutz, additional, Bigi, Sandra, additional, Derfuss, Tobias, additional, Gobbi, Claudio, additional, Kamber, Nicole, additional, Kamm, Christian P., additional, Kuhle, Jens, additional, Lalive, Patrice, additional, Müller, Stefanie, additional, Papadopoulou, Athina, additional, Pot, Caroline, additional, Zecca, Chiara, additional, and Chan, Andrew, additional

Published
2022
Full Text
View/download PDF

44. Brain functional connectivity alterations associated with neuropsychological performance 6–9 months following SARS‐CoV ‐2 infection

Author

Voruz, Philippe, primary, Cionca, Alexandre, additional, Jacot de Alcântara, Isabele, additional, Nuber‐Champier, Anthony, additional, Allali, Gilles, additional, Benzakour, Lamyae, additional, Lalive, Patrice H., additional, Lövblad, Karl O., additional, Braillard, Olivia, additional, Nehme, Mayssam, additional, Coen, Matteo, additional, Serratrice, Jacques, additional, Reny, Jean‐Luc, additional, Pugin, Jérôme, additional, Guessous, Idris, additional, Ptak, Radek, additional, Landis, Basile N., additional, Adler, Dan, additional, Griffa, Alessandra, additional, Van De Ville, Dimitri, additional, Assal, Frédéric, additional, and Péron, Julie A., additional

Published
2022
Full Text
View/download PDF

45. Comparative effectiveness of autologous hematopoietic stem cell transplant vs Fingolimod, Natalizumab, and Ocrelizumab in highly active relapsing-remitting multiple sclerosis

Author

Kalincik, Tomas, Sharmin, Sifat, Roos, Izanne, Freedman, Mark S., Atkins, Harold, Burman, Joachim, Massey, Jennifer, Sutton, Ian, Withers, Barbara, Macdonell, Richard, Grigg, Andrew, Torkildsen, Øivind, Bo, Lars, Lehmann, Anne Kristine, Havrdova, Eva Kubala, Krasulova, Eva, Trněný, Marek, Kozak, Tomas, van der Walt, Anneke, Butzkueven, Helmut, McCombe, Pamela, Skibina, Olga, Lechner-Scott, Jeannette, Willekens, Barbara, Cartechini, Elisabetta, Ozakbas, Serkan, Alroughani, Raed, Kuhle, Jens, Patti, Francesco, Duquette, Pierre, Lugaresi, Alessandra, Khoury, Samia J., Slee, Mark, Turkoglu, Recai, Hodgkinson, Suzanne, John, Nevin, Maimone, Davide, Sa, Maria Jose, van Pesch, Vincent, Gerlach, Oliver, Laureys, Guy, Van Hijfte, Liesbeth, Karabudak, Rana, Spitaleri, Daniele, Csepany, Tunde, Gouider, Riadh, Castillo-Triviño, Tamara, Taylor, Bruce, Sharrack, Basil, Snowden, John A., Horakova, Dana, Buzzard, Katherine, Terzi, Murat, Prat, Alexandre, Girard, Marc, Grammond, Pierre, Barnett, Michael, Stewart, Grace, Onofrj, Marco, Izquierdo, Guillermo, Eichau, Sara, Grand'Maison, Francois, Prevost, Julie, Van Wijmeersch, Bart, Amato, Maria Pia, Shaygannejad, Vahid, Boz, Cavit, Bolaños, Ricardo Fernandez, Soysal, Aysun, Ramo-Tello, Cristina, Solaro, Claudio, Gobbi, Claudio, Cabrera-Gomez, Jose Antonio, Roullet, Etienne, Zwanikken, Cees, Den braber-Moerland, Leontien, Deri, Norma, Saladino, Maria Laura, Cristiano, Edgardo, Rojas, Juan Ignacio, Vrech, Carlos, Shaw, Cameron, Shuey, Neil, Boggild, Mike, Tan, Ik Lin, Hardy, Todd, Decoo, Danny, Moore, Fraser, Oh, Jiwon, Lalive, Patrice, Ampapa, Radek, Petersen, Thor, Oreja-Guevara, Celia, Perez Sempere, Angel, Dominguez, Jose Andres, Besora, Sarah, Hughes, Stella, Gray, Orla, Grigoriadis, Nikolaos, Piroska, Imre, Rozsa, Csilla, Kasa, Krisztian, Simo, Magdolna, Kovacs, Krisztina, Sas, Attila, Dobos, Eniko, Rajda, Cecilia, McGuigan, Chris, Mason, Deborah, Schepel, Jan, Alkhaboori, Jabir, Rio, Maria Edite, Mihaela, Simu, Al-Harbi, Talal, Altintas, Ayse, Kister, Ilya, Marriott, Mark, Kilpatrick, Trevor, King, John, Nguyen, Ai-Lan, Dwyer, Chris, Monif, Mastura, Taylor, Lisa, Diamanti, Matteo, Chisari, Clara, Toscano, Simona, Salvatore, Lo Fermo, Larochelle, Catherine, De Luca, Giovanna, Di Tommaso, Valeria, Travaglini, Daniela, Pietrolongo, Erika, di Ioia, Maria, Farina, Deborah, Mancinelli, Luca, Hupperts, Raymond, Olascoaga, Javier, Saiz, Albert, Zivadinov, Robert, Benedict, Ralph, Verheul, Freek, Fabis-Pedrini, Marzena, Mrabet, Saloua, Garber, Justin, Sanchez-Menoyo, Jose Luis, Aguera-Morales, Eduardo, Blanco, Yolanda, Al-Asmi, Abdullah, Weinstock-Guttman, Bianca, Fragoso, Yara, de Gans, Koen, and Kermode, Allan

Subjects
Human medicine
Abstract

you are agreeing to our Cookie Policy | Continue JAMA Network HomeJAMA Neurology This Issue Views 2,357 Citations 0 60 Full Text Share Comment Original Investigation May 15, 2023 Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis Tomas Kalincik, MD, PhD1,2; Sifat Sharmin, PhD1,2; Izanne Roos, MBChB, PhD1,2; Mark S. Freedman, MD3; Harold Atkins, MD4; Joachim Burman, MD, PhD5; Jennifer Massey, MBBS, PhD6,7; Ian Sutton, MBBS, PhD6,8; Barbara Withers, MD, PhD7,9; Richard Macdonell, MD, PhD10,11; Andrew Grigg, MD, PhD11,12; Øivind Torkildsen, MD, PhD13; Lars Bo, MD, PhD13; Anne Kristine Lehmann, MD, PhD14; Eva Kubala Havrdova, MD, PhD15; Eva Krasulova, MD, PhD15; Marek Trněný, MD, PhD16; Tomas Kozak, MD, PhD17; Anneke van der Walt, MBBS, PhD18,19; Helmut Butzkueven, MBBS, PhD18,19; Pamela McCombe, MBBS20,21; Olga Skibina, MBBS18,22,23; Jeannette Lechner-Scott, MD, PhD24,25; Barbara Willekens, MD, PhD26,27; Elisabetta Cartechini, MD28; Serkan Ozakbas, MD29; Raed Alroughani, MD30; Jens Kuhle, MD, PhD31; Francesco Patti, MD32,33; Pierre Duquette, MD34; Alessandra Lugaresi, MD, PhD35,36; Samia J. Khoury, MD, PhD37; Mark Slee, MD, PhD38; Recai Turkoglu, MD39; Suzanne Hodgkinson, MD40; Nevin John, MD, PhD41,42; Davide Maimone, MD43; Maria Jose Sa, MD44; Vincent van Pesch, MD, PhD45,46; Oliver Gerlach, MD, PhD47,48; Guy Laureys, MD49; Liesbeth Van Hijfte, MD49; Rana Karabudak, MD50; Daniele Spitaleri, MD51; Tunde Csepany, MD, PhD52; Riadh Gouider, MD53,54; Tamara Castillo-Triviño, MD55; Bruce Taylor, MD, PhD56,57; Basil Sharrack, MD, PhD58; John A. Snowden, MD, PhD59; and the MSBase Study Group Collaborators; and the MSBase Study Group Authors Author Affiliations JAMA Neurol. 2023;80(7):702-713. doi:10.1001/jamaneurol.2023.1184 editorial comment iconEditorial Comment Key Points Question What is the comparative effectiveness of autologous hematopoietic stem cell transplant (AHSCT) vs individual most potent disease-modifying therapies for relapsing-remitting multiple sclerosis (MS), such as natalizumab or ocrelizumab? Findings In this observational comparative effectiveness study of 4915 individuals using a composite cohort from specialized MS centers and the MSBase international registry, the effectiveness of AHSCT was compared with 1 medium-efficacy and 2 high-efficacy disease-modifying therapies (fingolimod, natalizumab, and ocrelizumab) in patients with relapsing-remitting MS, high frequency of relapses, and moderate disability. Over 5 years, AHSCT was associated with substantially lower relapse rate than fingolimod and marginally lower relapse rate than natalizumab and was also associated with a higher rate of recovery from disability compared with fingolimod and natalizumab, but no evidence of difference in clinical outcomes between AHSCT and ocrelizumab was found at 3-year follow-up. Meaning The results indicate that in relapsing-remitting MS, the clinical effectiveness of AHSCT is considerably superior to fingolimod and marginally superior to natalizumab. Abstract Importance Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS). Objective To compare the effectiveness of AHSCT vs fingolimod, natalizumab, and ocrelizumab in relapsing-remitting MS by emulating pairwise trials. Design, Setting, and Participants This comparative treatment effectiveness study included 6 specialist MS centers with AHSCT programs and international MSBase registry between 2006 and 2021. The study included patients with relapsing-remitting MS treated with AHSCT, fingolimod, natalizumab, or ocrelizumab with 2 or more years study follow-up including 2 or more disability assessments. Patients were matched on a propensity score derived from clinical and demographic characteristics. Exposure AHSCT vs fingolimod, natalizumab, or ocrelizumab. Main outcomes Pairwise-censored groups were compared on annualized relapse rates (ARR) and freedom from relapses and 6-month confirmed Expanded Disability Status Scale (EDSS) score worsening and improvement. Results Of 4915 individuals, 167 were treated with AHSCT; 2558, fingolimod; 1490, natalizumab; and 700, ocrelizumab. The prematch AHSCT cohort was younger and with greater disability than the fingolimod, natalizumab, and ocrelizumab cohorts; the matched groups were closely aligned. The proportion of women ranged from 65% to 70%, and the mean (SD) age ranged from 35.3 (9.4) to 37.1 (10.6) years. The mean (SD) disease duration ranged from 7.9 (5.6) to 8.7 (5.4) years, EDSS score ranged from 3.5 (1.6) to 3.9 (1.9), and frequency of relapses ranged from 0.77 (0.94) to 0.86 (0.89) in the preceding year. Compared with the fingolimod group (769 [30.0%]), AHSCT (144 [86.2%]) was associated with fewer relapses (ARR: mean [SD], 0.09 [0.30] vs 0.20 [0.44]), similar risk of disability worsening (hazard ratio [HR], 1.70; 95% CI, 0.91-3.17), and higher chance of disability improvement (HR, 2.70; 95% CI, 1.71-4.26) over 5 years. Compared with natalizumab (730 [49.0%]), AHSCT (146 [87.4%]) was associated with marginally lower ARR (mean [SD], 0.08 [0.31] vs 0.10 [0.34]), similar risk of disability worsening (HR, 1.06; 95% CI, 0.54-2.09), and higher chance of disability improvement (HR, 2.68; 95% CI, 1.72-4.18) over 5 years. AHSCT (110 [65.9%]) and ocrelizumab (343 [49.0%]) were associated with similar ARR (mean [SD], 0.09 [0.34] vs 0.06 [0.32]), disability worsening (HR, 1.77; 95% CI, 0.61-5.08), and disability improvement (HR, 1.37; 95% CI, 0.66-2.82) over 3 years. AHSCT-related mortality occurred in 1 of 159 patients (0.6%). Conclusion In this study, the association of AHSCT with preventing relapses and facilitating recovery from disability was considerably superior to fingolimod and marginally superior to natalizumab. This study did not find evidence for difference in the effectiveness of AHSCT and ocrelizumab over a shorter available follow-up time.

Published
2023

46. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Author

Sharmin, Sifat, Roos, Izanne, Simpson-Yap, Steve, Malpas, Charles, Sánchez, Marina M, Ozakbas, Serkan, Horakova, Dana, Havrdova, Eva K, Patti, Francesco, Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Boz, Cavit, Zakaria, Magd, Onofrj, Marco, Lugaresi, Alessandra, Weinstock-Guttman, Bianca, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Terzi, Murat, Amato, Maria Pia, Karabudak, Rana, Grand'Maison, Francois, Khoury, Samia J, Grammond, Pierre, Lechner-Scott, Jeannette, Buzzard, Katherine, Skibina, Olga, van der Walt, Anneke, Butzkueven, Helmut, Turkoglu, Recai, Altintas, Ayse, Maimone, Davide, Kermode, Allan, Shalaby, Nevin, Pesch, Vincent V, Butler, Ernest, Sidhom, Youssef, Gouider, Riadh, Mrabet, Saloua, Gerlach, Oliver, Soysal, Aysun, Barnett, Michael, Kuhle, Jens, Hughes, Stella, Maria J, Sa, Hodgkinson, Suzanne, Oreja-Guevara, Celia, Ampapa, Radek, Petersen, Thor, Ramo-Tello, Cristina, Spitaleri, Daniele, Mccombe, Pamela, Taylor, Bruce, Prevost, Julie, Foschi, Matteo, Slee, Mark, Mcguigan, Chris, Laureys, Guy, Hijfte, Liesbeth V, de Gans, Koen, Solaro, Claudio, Jiwon, Oh, Macdonell, Richard, Aguera-Morales, Eduardo, Singhal, Bhim, Gray, Orla, Garber, Justin, Wijmeersch, Bart V, Simu, Mihaela, Triviño, Tamara C, Sanchez-Menoyo, Jose L, Khurana, Dheeraj, Al-Asmi, Abdullah, Al-Harbi, Talal, Deri, Norma, Fragoso, Yara, Lalive, Patrice H, Sinnige, L G F, Shaw, Cameron, Shuey, Neil, Csepany, Tunde, Sempere, Angel P, Moore, Fraser, Decoo, Danny, Willekens, Barbara, Gobbi, Claudio, Massey, Jennifer, Hardy, Todd, Parratt, John, and Kalincik, Tomas

Subjects
secondary progressive multiple sclerosis, health expenditure, disease-modifying therapy, geography, latitude
Published
2023

47. Machine-learning-based prediction of disability progression in multiple sclerosis: an observational, international, multi-center study

Author

De Brouwer, Edward, primary, Becker, Thijs, additional, Werthen-Brabants, Lorin, additional, Dewulf, Pieter, additional, Iliadis, Dimitrios, additional, Dekeyser, Cathérine, additional, Laureys, Guy, additional, Van Wijmeersch, Bart, additional, Popescu, Veronica, additional, Dhaene, Tom, additional, Deschrijver, Dirk, additional, Waegeman, Willem, additional, De Baets, Bernard, additional, Stock, Michiel, additional, Horakova, Dana, additional, Patti, Francesco, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Girard, Marc, additional, Prat, Alexandre, additional, Lugaresi, Alessandra, additional, Grammond, Pierre, additional, Kalincik, Tomas, additional, Alroughani, Raed, additional, Grand’Maison, Francois, additional, Skibina, Olga, additional, Terzi, Murat, additional, Lechner-Scott, Jeannette, additional, Gerlach, Oliver, additional, Khoury, Samia J., additional, Cartechini, Elisabetta, additional, Van Pesch, Vincent, additional, Sa, Maria Jose, additional, Weinstock-Guttman, Bianca, additional, Blanco, Yolanda, additional, Ampapa, Radek, additional, Spitaleri, Daniele, additional, Solaro, Claudio, additional, Maimone, Davide, additional, Soysal, Aysun, additional, Iuliano, Gerardo, additional, Gouider, Riadh, additional, Castillo-Triviño, Tamara, additional, Sanchez-Menoyo, Jose Luis, additional, van der Walt, Anneke, additional, Oh, Jiwon, additional, Aguera-Morales, Eduardo, additional, Altintas, Ayse, additional, Al-Asmi, Abdullah, additional, de Gans, Koen, additional, Fragoso, Yara, additional, Csepany, Tunde, additional, Hodgkinson, Suzanne, additional, Deri, Norma, additional, Al-Harbi, Talal, additional, Taylor, Bruce, additional, Gray, Orla, additional, Lalive, Patrice, additional, Rozsa, Csilla, additional, McGuigan, Chris, additional, Kermode, Allan, additional, Perez sempere, Angel, additional, Mihaela, Simu, additional, Simo, Magdolna, additional, Hardy, Todd, additional, Decoo, Danny, additional, Hughes, Stella, additional, Grigoriadis, Nikolaos, additional, Sas, Attila, additional, Vella, Norbert, additional, Moreau, Yves, additional, and Peeters, Liesbet, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results